SEC Info - Shire plc, et al. - ‘SC 13G’ on 8/7/02 re: Immunogen Inc

SEC Info℠

Home

Help

Please Sign In

Shire plc, et al. – ‘SC 13G’ on 8/7/02 re: Immunogen Inc

On: Wednesday, 8/7/02, at 4:42pm ET · Accession #: 950162-2-959 · File #: 5-40774

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/07/02  Shire plc                         SC 13G                 1:11K  Immunogen Inc                     Cahill Gordon & … LLP/FA
          Shire Biochem, Inc.

Statement of Beneficial Ownership — Schedule 13G
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G      Statement of Beneficial Ownership                      8     25K

Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Address of Issuer's Principal Executive Offices: Address of Principal Business Office: Certification: Citizenship: CUSIP Number: Identification and Classification of Members of the Group: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: Name of Issuer: ImmunoGen, Inc Name of Person Filing: Notice of Dissolution of Group: Ownership: Ownership of Five Percent or Less of a Class: Ownership of More than Five Percent on Behalf of Another Person: Title of Class of Securities:
1	1st Page - Filing Submission
4	Item 1(a). Name of Issuer: ImmunoGen, Inc
"	Item 1(b). Address of Issuer's Principal Executive Offices:
"	Item 2(a). Name of Person Filing:
"	Item 2(b). Address of Principal Business Office:
"	Item 2(c). Citizenship:
"	Item 2(d). Title of Class of Securities:
"	Item 2(e). CUSIP Number:
"	Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:
5	Item 4. Ownership:
"	Item 5. Ownership of Five Percent or Less of a Class:
"	Item 6. Ownership of More than Five Percent on Behalf of Another Person:
"	Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
"	Item 8. Identification and Classification of Members of the Group:
6	Item 9. Notice of Dissolution of Group:
"	Item 10. Certification:

SC 13G 1st Page of 8 TOC ↑Top Previous Next ↓Bottom Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

 Under the Securities Exchange Act of 1934

 ImmunoGen, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)

Common Stock, $.01 Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)

 45253H101
--------------------------------------------------------------------------------
(CUSIP Number)

--------------------------------------------------------------------------------

 July 29, 2002
--------------------------------------------------------------------------------
 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 
is filed:                                                                       

/ /     Rule 13d-1(b)                                 
/X/     Rule 13d-1(c)                                 
/ /     Rule 13d-1(d)                                 

*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the       
disclosures provided in a prior cover page.                                     

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of   
1934 ("Act") or otherwise subject to the liabilities of that section of the Act 
but shall be subject to all other provisions of the Act (however, see the       
Notes).                                                                         

SC 13G 2nd Page of 8 TOC 1st Previous Next ↓Bottom Just 2nd
CUSIP 45253H101            SCHEDULE 13G                                   -2-   

--------- ----------------------------------------------------------------------
1.     Names of Reporting Persons.                                        
I.R.S. Identification Nos. of above persons (entities only).

Shire BioChem Inc.                                          
--------- ----------------------------------------------------------------------
2.     Check the Appropriate Box if a Member of a Group                   
     (See Instructions)                                        (a) / /
                                                               (b) / /

--------- ----------------------------------------------------------------------
3.     SEC Use Only                                                       

--------- ----------------------------------------------------------------------
4.     Citizenship or Place of Organization                               

Canada                                                      
--------- ----------------------------------------------------------------------
5.    Sole Voting Power 

0           
                           ------ ----------------------------------------------
Number of           6.    Shared Voting Power                   
Shares                                                        
Beneficially                4,096,098                               
                           ------ ----------------------------------------------
Owned by Each         7.    Sole Dispositive Power                  
Reporting                                                       
Person With:                0                                       
                           ------ ----------------------------------------------
      8.    Shared Dispositive Power

4,096,098   
-------------------------- ------ ----------------------------------------------
9.     Aggregate Amount Beneficially Owned by Each Reporting Person       

4,096,098                                                   
--------- ----------------------------------------------------------------------
10.     Check box if the Aggregate Amount in Row (9) Excludes               
       Certain Shares (See Instructions)                               / /

--------- ----------------------------------------------------------------------
11.     Percent of Class Represented by Amount in Row (9)                   

9.26%                                                       
--------- ----------------------------------------------------------------------
12.     Type of Reporting Person (See Instructions)                         

CO                                                          

SC 13G 3rd Page of 8 TOC 1st Previous Next ↓Bottom Just 3rd
CUSIP 45253H101            SCHEDULE 13G                                   -3-   

--------- ----------------------------------------------------------------------
1.     Names of Reporting Persons.                                        
I.R.S. Identification Nos. of above persons (entities only).

Shire Pharmaceuticals Group Plc                             
--------- ----------------------------------------------------------------------
2.     Check the Appropriate Box if a Member of a Group                   
       (See Instructions)                                          (a) / /
                                                                   (b) / /

--------- ----------------------------------------------------------------------
3.     SEC Use Only                                                       

--------- ----------------------------------------------------------------------
4.     Citizenship or Place of Organization                               

England and Wales                                           
--------- ----------------------------------------------------------------------
5.    Sole Voting Power 

0           
                           ------ ----------------------------------------------
Number of           6.    Shared Voting Power                   
Shares                                                        
Beneficially                4,096,098                               
                           ------ ----------------------------------------------
Owned by Each         7.    Sole Dispositive Power                  
Reporting                                                       
Person With:                0                                       
                           ------ ----------------------------------------------
      8.    Shared Dispositive Power

4,096,098   
-------------------------- ------ ----------------------------------------------
9.     Aggregate Amount Beneficially Owned by Each Reporting Person       

4,096,098                                                   
--------- ----------------------------------------------------------------------
10.     Check box if the Aggregate Amount in Row (9) Excludes               
     Certain Shares (See Instructions)                             / /

--------- ----------------------------------------------------------------------
11.     Percent of Class Represented by Amount in Row (9)                   

9.26%                                                       
--------- ----------------------------------------------------------------------
12.     Type of Reporting Person (See Instructions)                         

CO                                                          

SC 13G 4th Page of 8 TOC 1st Previous Next ↓Bottom Just 4th
CUSIP 45253H101            SCHEDULE 13G                                   -4-   

Item 1(a). Name of Issuer:                                                      
ImmunoGen, Inc.                                             

Item 1(b). Address of Issuer's Principal Executive Offices:                     

128 Sidney Street, Cambridge, MA 02139                      

Item 2(a). Name of Person Filing:                                               

      This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons")                     

(i)      Shire BioChem Inc.                                   
(ii)     Shire Pharmaceuticals Group Plc                      

Item 2(b). Address of Principal Business Office:                                

(i)      Shire BioChem Inc.                                   
275 Armand-Frappier Blvd.                   
Laval, Quebec                               
Canada H7V 4A7                              

(ii)     Shire Pharmaceuticals Group Plc                      
Hampshire International Business Park       
Chineham, Basingstoke                       
RG24 8EP                                    
United Kingdom                              

Item 2(c). Citizenship:                                                         

(i)      Shire BioChem is a Canadian corporation.             
      (ii)     Shire Pharmaceuticals Group Plc is a public limited company
  organized under the laws of England and Wales.

Item 2(d). Title of Class of Securities:                                        

Common Stock, $.01 par value (the "Shares")                   

Item 2(e). CUSIP Number:                                                        

45253H101                                                     

Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or            
240.13d-2(b) or (c), check whether the person is a:             

This Item 3 is not applicable                                 

SC 13G 5th Page of 8 TOC 1st Previous Next ↓Bottom Just 5th
CUSIP 45253H101            SCHEDULE 13G                                   -5-   

Item 4. Ownership:                                                              

Shire BioChem Inc.                                              

        (a)      Amount beneficially owned:                            4,096,098

        (b)      Percent of class:                                         9.26%

(c)      Number of shares as to which such person has:          
(i)        sole power to vote or to direct    
                            the vote:                                          0
(ii)       shared power to vote or to direct  
                            the vote:                                  4,096,098
(iii)      sole power to dispose or to direct 
                            the disposition of:                                0
 (iv)       shared power to dispose or to direct
                            the disposition of:                        4,096,098

Shire Pharmaceuticals Group Plc                                 

        (a)      Amount beneficially owned:                         4,096,098(1)

        (b)      Percent of class:                                         9.26%

(c)      Number of shares as to which such person has:          
(i)        sole power to vote or to direct    
                            the vote:                                          0
(ii)       shared power to vote or to direct  
                            the vote:                                  4,096,098
(iii)      sole power to dispose or to direct 
                            the disposition of:                                0
 (iv)       shared power to dispose or to direct
                            the disposition of:                        4,096,098

---------                                                             

(1): All of the Shares are held by Shire BioChem Inc., a wholly owned 
subsidiary of Shire Pharmaceuticals Group Plc.              

Item 5. Ownership of Five Percent or Less of a Class:                           

Not Applicable                                                

Item 6. Ownership of More than Five Percent on Behalf of Another Person:        

Not Applicable                                                

Item 7. Identification and Classification of the Subsidiary Which Acquired the  
Security Being Reported on by the Parent Holding Company:       

Not Applicable                                                

Item 8. Identification and Classification of Members of the Group:              

Not Applicable                                                

SC 13G 6th Page of 8 TOC 1st Previous Next ↓Bottom Just 6th
CUSIP 45253H101            SCHEDULE 13G                                   -6-   

Item 9. Notice of Dissolution of Group:                                         

Not Applicable                                                

Item 10. Certification:                                                         

   By signing below, I certify that, to the best of my knowledge and
        belief, the securities referred to above were acquired and are held in
        the ordinary course of business and were not acquired and are not held
      for the purpose of or with the effect of changing or influencing the
       control of the issuer of the securities and were not acquired and are
    not held in connection with or as a participant in any transaction
having that purpose or effect.                                

 SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify  
that the information set forth in this statement is true, complete and correct. 

Dated: August 7, 2002                                                           
SHIRE BIOCHEM INC.      

By:      Angus Russell  
                                     -------------------------------------------
             Name: Angus Russell
         Title: Director

Dated: August 7, 2002                                                           
       SHIRE PHARMACEUTICALS GROUP PLC

By:      Angus Russell  
                                     -------------------------------------------
             Name: Angus Russell
                       Title: Group Finance Director

SC 13G 7th Page of 8 TOC 1st Previous Next ↓Bottom Just 7th
CUSIP 45253H101            SCHEDULE 13G                                   -7-   

 EXHIBIT INDEX

                                                                      Page No.

A. Joint Filing Agreement dated August 7, 2002 by and among Shire BioChem       
Inc. and Shire Pharmaceuticals Group                                      
Plc.................................................................... 8 

SC 13G Last Page of 8 TOC 1st Previous Next ↓Bottom Just 8th
CUSIP 45253H101            SCHEDULE 13G                                   -8-   

 EXHIBIT A
JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with  
respect to the Common Stock of ImmunoGen, Inc. dated as of August , 2002 is, and
any amendments thereto signed by each of the undersigned shall be, filed on     
behalf of each of us pursuant to and in accordance with the provisions of Rule  
13d-1(f) under the Securities Exchange Act of 1934.                             

Dated: August 7, 2002                                                           
SHIRE BIOCHEM INC.  

  By:      Angus Russell
                                       -----------------------------------------
                 Name: Angus Russell
             Title: Director

Dated: August 7, 2002                                                           
           SHIRE PHARMACEUTICALS GROUP PLC

  By:      Angus Russell
                                       -----------------------------------------
                 Name: Angus Russell
                           Title: Group Finance Director

SC 13G	1st Page of 8	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

SC 13G	2nd Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 2nd

SC 13G	3rd Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 3rd

SC 13G	4th Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 4th

SC 13G	5th Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 5th

SC 13G	6th Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 6th

SC 13G	7th Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 7th

SC 13G	Last Page of 8	TOC	1st	Previous	Next	↓Bottom	Just 8th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘SC 13G’ Filing	Date	First	Last	Other Filings

Filed on:	8/7/02	6	8
	7/29/02	1		8-K
				List all Filings

↑Top

Filing Submission 0000950162-02-000959 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Shire plc, et al. – ‘SC 13G’ on 8/7/02 re: Immunogen Inc

On: Wednesday, 8/7/02, at 4:42pm ET · Accession #: 950162-2-959 · File #: 5-40774

Statement of Beneficial Ownership — Schedule 13GFiling Table of Contents

Document Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

Statement of Beneficial Ownership — Schedule 13G
Filing Table of Contents